Achieving an Earlier Diagnosis in Pulmonary Arterial Hypertension
In this module of a Four-Part Expert Interview Series, Evelyn Horn, MD, along with Aaron B. Waxman, MD, PhD, course chair, will discuss best practices for achieving an earlier diagnosis in pulmonary arterial hypertension (PAH). Data supporting early intervention will be analyzed along with risk factors for PAH and screening recommendations derived from current guidelines. The faculty will review methodology ...
View Course
Understanding Lipoprotein(a)- Novel Therapeutics to Reduce Lp(a) Levels and Improve Cardiovascular Outcomes
This CME/CNE program will highlight content presented at the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany. The three expert faculty, led by Dr. Patrick M. Moriarty, will assess the role of lipoprotein(a)- novel therapeutics in reducing Lp(a) levels and improving cardiovascular outcomes. A state of the science of lipoprotein(a), including the mechanism of action, subtypes and prevalence, ...
View Course
View Course
Identifying Financial and/or Treatment Access Barriers: Patient Perspectives
In this module of a Four-Part Expert Interview Series, Dr. James A. Underberg, along with Dr Christopher P. Cannon, course chair, will identify barriers to caring for dyslipidemia patients. There barriers will include financial and other patient-related obstacles. This discussion will incorporate strategies to improve access to PCSK9 inhibitors, in turn leading to improved patient outcomes. Cardiologists, internists, and other ...
View Course
View Course
Clinical Trial Analysis of PCSK9 Inhibitors: The Impact of Real-World Cardiovascular Outcomes
In this module of a Four-Part Expert Interview Series, Dr. Michael J. Blaha, along with Dr Christopher P. Cannon, course chair, will explore the role of PCSK9 inhibitors in the treatment of dyslipidemia patients and the impact of real-world cardiovascular outcomes. This discussion will aid physicians in providing optimal care in clinical practice. Cardiologists, internists, and other healthcare professionals involved ...
View Course
View Course
The Role of PCSK9 Inhibitors in Reducing CV Risk: Patient Selection Criteria and Treatment Initiation Tactics
In this module of a Four-Part Expert Interview Series, Dr. Robert P. Giugliano, along with Dr Christopher P. Cannon, course chair, will examine the role of PCSK9 inhibitors in reducing CV risk. Dr. Guigliano will review optimal patient selection criteria and how it can be applied in daily practice. This module will allow learners to understand the relationship between LDL-C ...
View Course
View Course
Further Insights in Lowering LDL Cholesterol: Managing Atherosclerotic Disease in High-Risk Patients
In this module of a Four-Part Expert Interview Series, Dr. Marc P. Bonaca, along with Dr. Christopher P. Cannon, course chair, will discuss options for lowering LDL cholesterol in dyslipidemia patients. This will include recent outcomes from clinical trials and the diagnostic criteria of peripheral artery disease. Enabling physicians to recognize physical indicators of PAD will maximize treatment efforts in ...
View Course
View Course
Scientific Updates in the Reversal of Direct Oral Anticoagulants for Patients with an Acute Major Bleed
This continuing education activity will review optimal treatment strategies and recent clinical trial data for patients who require emergent reversal of their direct oral anticoagulant therapy as presented at the American College of Cardiology 2018 in Orlando, Florida. Three expert faculty will analyze clinical profiles of reversal agents and current strategies to treat direct oral anticoagulant associated bleeds in emergent ...
View Course
View Course
Advancements in the Prevention and Management of Stroke
This CME/CNE webcast will highlight recent advancements in the prevention and management of stroke. The expert faculty will discuss best practices for assessing risk as well as the modifiable risk factors of stroke. Recent clinical trial data, including that of combination therapy, will be analyzed, as well as strategies for managing the comorbidities that commonly accompany stroke. Best practices for ...
View Course
View Course
The New Era of Preventive Cardiology: Applying PCSK9 Inhibitor Therapeutics to Prevent Heart Attack and Stroke
This CME/CNE program is derived from content presented at the National Lipid Association 2018 Scientific Sessions in Las Vegas, Nevada. The five expert faculty, led by Dr. Alan S. Brown, will review best practices for assessing the risk of cardiovascular disease (CVD). Recently released data, including the results of the ODYSSEY and FOURIER trials, will be outlined followed by a ...
View Course
View Course
Navigating the Role of PCSK9 Inhibitors in the Prevention of Cardiovascular Events
This CME activity will review optimal treatment strategies and recent clinical trial data for patients with dyslipidemia, as presented at the American College of Cardiology 2018 in Orlando, Florida. Four expert faculty, led by Dr. Christopher Cannon, will analyze the science of LDL cholesterol and how it relates to cardiovascular events. Recent clinical trial data for PCSK9 inhibitors, including data ...
View Course
View Course
